US regulators grant orphan drug status to AstraZeneca’s Imfinzi cancer drug
Imfinzi recently showed in a late-stage study that, when combined with chemotherapy, it had a “clinically meaningful” effect on overall survival
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 33 of 55
AstraZeneca gets two positive opinions from European Medicines Agency committee
The Committee for Medicinal Products for Human Use (CHMP) recommended that diabetes medicine Forxiga should have its marketing authorisation updated to include cardiovascular data from recent clinical trials
AstraZeneca gets EU approval for Lynparza as ovarian cancer treatment
Pharma giant had been targeting annual peak sales of $2bn for the drug, of which $400mln was from ovarian cancer
AstraZeneca sees further encouraging effects from leukaemia treatment Calquence
Interim analysis of a phase III clinical trial has revealed that after 12 months, 88% of people saw no progression of the disease if they were given the drug
AstraZeneca drug for chronic lymphocytic leukaemia successfully navigates phase III trial
The results will “serve as the foundation for regulatory submissions later this year", said AZ’s vice president of oncology, José Baselga
AstraZeneca reports positive results from trial of pancreatic cancer treatment
Results from the trial of Lynparza showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse
Immuno-oncology: All you wanted to know but were too afraid to ask
Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers
Is London's fickle funding appetite part of Lasker's 'disastrous' cycle?
Stock market sage Bernard Lasker once said: “I can feel it coming...A whole new round of disastrous speculation, with all the familiar stages in order: blue-chip boom, then a fad for secondary issues, then an over-the-counter play, then a g
BHP, AstraZeneca and Shell among world’s top divi payers as shareholders gear up for record year of returns
Asset Manager Janus Henderson is predicting that global dividend pay-outs will reach almost US$1.5trn in 2019
Pharma stocks head south as Trump forces them to display drug prices in TV ads
“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”
AstraZeneca gets US regulatory green light for slow-release diabetes drug
Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control
Archive
Loungers sees good start to first day of trading on AIM
A look at some of the biggest risers and fallers in London on Monday
AstraZeneca first-quarter profits double as product sales revival continues but cash still a worry
The oncology portfolio has helped to turn around Astra’s product sales, which for years had been falling as key drugs went off-patent
Investments and investor services
FTSE 100 closes just in red as crude price decline hits resource stocks
The UK blue-chip index finished down nearly six points at 7,428 on Friday
Archive
City set for unusually busy Friday with RBS leading the way
Alongside RBS, AstraZeneca, Just Eat, WPP and Pearson are all due to publish first-quarter trading updates on Friday
Investments and investor services
FTSE 100 closes at near seven month high as no news is deemed good news
The UK blue-chip index finished up around 63 points at 7,523
While UK dividends hit record £19.7bn in first quarter, some FTSE 100 companies could be headed for cuts
Basic measures like dividend cover suggest a number of blue chips might be struggling to maintain their payouts at current levels
Archive
Once Easter is over, a plethora of blue-chip big guns are set to report trading updates and results
The Week Ahead will bring updates from the likes of Royal Bank of Scotland and Barclays, plus drugs giant AstraZeneca, and media groups WPP, Pearson and WPP
AstraZeneca’s new Japanese cancer drug tipped to rack up billions in annual sales
Liberum thinks trastuzumab deruxtecan can generate peak sales of more than US$3bn, given the drug’s potential in a host of cancer indications
AstraZeneca is still not converting top-line momentum into cash-flow, says UBS
Astra has affected a “momentous turnaround” in sales growth, but it has struggled to turn that top-line momentum into cash flow, according to UBS